Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Tacchetti P, Rocchi S, Zamagni E, Barbato S, Rizzello I, De Cicco G, Pantani L, Mancuso K, Fusco A, Dozza L, Ursi M, Favero E, Terragna C, Testoni N, Cavo M. Tacchetti P, et al. Among authors: rizzello i. Am J Hematol. 2022 Dec;97(12):1607-1615. doi: 10.1002/ajh.26747. Epub 2022 Oct 18. Am J Hematol. 2022. PMID: 36198076 Free PMC article.
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.
Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M. Zamagni E, et al. Among authors: rizzello i. Clin Cancer Res. 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15. Clin Cancer Res. 2015. PMID: 26078390
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Tacchetti P, Cavo M, Rocchi S, Pezzi A, Pantani L, Brioli A, Testoni N, Terragna C, Zannetti BA, Mancuso K, Marzocchi G, Borsi E, Martello M, Rizzello I, Zamagni E. Tacchetti P, et al. Among authors: rizzello i. Leuk Lymphoma. 2016 Sep;57(9):2058-64. doi: 10.3109/10428194.2015.1124994. Epub 2016 Jan 14. Leuk Lymphoma. 2016. PMID: 26763357
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Tacchetti P, Pezzi A, Zamagni E, Pantani L, Rocchi S, Zannetti BA, Mancuso K, Rizzello I, Cavo M. Tacchetti P, et al. Among authors: rizzello i. Haematologica. 2017 Mar;102(3):e104-e107. doi: 10.3324/haematol.2016.154070. Epub 2016 Dec 1. Haematologica. 2017. PMID: 27909220 Free PMC article. No abstract available.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA, Tacchetti P, Pantani L, Gamberi B, Tosi P, Rocchi S, Cellini C, Ronconi S, Pezzi A, Mancuso K, Rizzello I, Caratozzolo I, Martello M, Dozza L, Cavo M, Zamagni E. Zannetti BA, et al. Among authors: rizzello i. Ann Hematol. 2017 Dec;96(12):2071-2078. doi: 10.1007/s00277-017-3140-5. Epub 2017 Oct 24. Ann Hematol. 2017. PMID: 29063955 Clinical Trial.
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.
Mancuso K, Tacchetti P, Pantani L, Rocchi S, Rizzello I, Caratozzolo I, De Cicco G, Fusco A, Testoni N, Terragna C, Marzocchi G, Martello M, Borsi E, Dozza L, Cavo M, Zamagni E. Mancuso K, et al. Among authors: rizzello i. Bone Marrow Transplant. 2020 Sep;55(9):1865-1867. doi: 10.1038/s41409-020-0844-2. Epub 2020 Feb 26. Bone Marrow Transplant. 2020. PMID: 32103147 No abstract available.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni Bezzi C, Scalese M, Dozza L, Marzocchi G, Martello M, Barilà G, Antonioli E, Staderini M, Buda G, Petrini M, Cea M, Quaresima M, Furlan A, Bonalumi A, Cavo M, Zamagni E. Rocchi S, et al. Among authors: rizzello i. Hematol Oncol. 2021 Feb;39(1):41-50. doi: 10.1002/hon.2820. Epub 2020 Nov 1. Hematol Oncol. 2021. PMID: 33085797 Clinical Trial.
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Rizzello I, Cavo M, Dozza L, Rivolti E, Petrucci MT, De Stefano V, Antonioli E, Tosi P, D'Agostino M, Morè S, Gozzetti A, Cea M, Barbato S, Tacchetti P, Pantani L, Mancuso K, Rocchi S, De Cicco G, Fusco A, Zamagni E. Rizzello I, et al. Leuk Lymphoma. 2021 Aug;62(8):1897-1906. doi: 10.1080/10428194.2021.1897805. Epub 2021 Mar 18. Leuk Lymphoma. 2021. PMID: 33733993
24 results